Literature DB >> 14738146

Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia.

Sílvia Casas1, Bálint Nagy, Erkki Elonen, Anna Aventín, Marcelo L Larramendy, Jorge Sierra, Tapani Ruutu, Sakari Knuutila.   

Abstract

Previous gene function analyses have indicated that HOXA9, DEK, CBL and CSF1R are aberrantly expressed in acute myeloid leukemia (AML). We analyzed the expression of these genes in a series of 41 adult patients with AML using quantitative real-time RT-PCR, and tested the association of the expression with the following hematologic and clinical parameters: age, FAB, immunophenotype and karyotype aberrations. A high proportion of the patients showed over- or underexpression of the analyzed genes. DEK was overexpressed in 98% of the cases, whereas CBL, CSF1R and HOXA9 were either overexpressed in 20%, 17% and 78% or underexpressed in 20%, 42% and 15% of the cases, respectively. Patients whose karyotype contained t(8;21)(q22;q22), showed lower relative expression of HOXA9 at a statistically significant level (p < 0.05). Bone marrow samples without expression of CD34 antigen were associated with either overexpression of DEK or HOXA9. Furthermore, an association was found between the AML-M2 subtype and lower expression of CBL, CSF1R or HOXA9, and between the AML-M5 subtype and CBL or CSF1R overexpression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14738146     DOI: 10.1080/1042819031000119299

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  20 in total

1.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 2.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 3.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

Review 4.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

6.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

7.  Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.

Authors:  Trisha M Wise-Draper; Rachael A Mintz-Cole; Teresa A Morris; David S Simpson; Kathryn A Wikenheiser-Brokamp; Mark A Currier; Timothy P Cripe; Gerard C Grosveld; Susanne I Wells
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

8.  DEK proto-oncogene expression interferes with the normal epithelial differentiation program.

Authors:  Trisha M Wise-Draper; Richard J Morreale; Teresa A Morris; Rachael A Mintz-Cole; Elizabeth E Hoskins; Scott J Balsitis; Nader Husseinzadeh; David P Witte; Kathryn A Wikenheiser-Brokamp; Paul F Lambert; Susanne I Wells
Journal:  Am J Pathol       Date:  2008-11-26       Impact factor: 4.307

9.  DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.

Authors:  Junying Wang; Limei Sun; Mingyue Yang; Wenting Luo; Ying Gao; Zihui Liu; Xueshan Qiu; Enhua Wang
Journal:  J Histochem Cytochem       Date:  2013-04-09       Impact factor: 2.479

Review 10.  Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications.

Authors:  Simone Fulda; Krishnaraj Rajalingam; Ivan Dikic
Journal:  EMBO Mol Med       Date:  2012-06-25       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.